• FDA Approves Two Oral JAK Inhibitors for Moderate to Severe Atopic Dermatitis

    8 days ago - By Medscape


    Read more ...

     

  • FDA approves Cibinqo for moderate to severe atopic dermatitis

    FDA approves Cibinqo for moderate to severe atopic dermatitis

    8 days ago - By Healio

    The FDA approved Cibinqo, an oral, once-daily JAK inhibitor, for the treatment of patients with moderate to severe atopic dermatitis, according to a press release.
    Supported by safety and efficacy data across three randomized, placebo-controlled phase 3 trials, Cibinqo demonstrated a consistent safety profile and improved skin clearance, extent of disease severity and itch among 1,600 patients with atopic dermatitis compared with placebo. The FDA recommended a dose of 100 mg and 200 mg among lower dosage non-responders.
    Additionally, they approved a 50 mg dose for patients
    Read more ...

     

  • FDA approves Rinvoq for atopic dermatitis

    FDA approves Rinvoq for atopic dermatitis

    8 days ago - By Healio

    The FDA approved Rinvoq, a selective JAK inhibitor, for the treatment of moderate to severe atopic dermatitis among patients aged 12 years and older, according to a press release.
    Supported by safety and efficacy results across three atopic dermatitis studies, Rinvoq 15 mg and 30 mg once daily monotherapy, or in conjunction with topical corticosteroids, met all primary and secondary endpoints at week 16. Some patients achieved higher levels of skin clearance as measured by the eczema area and severity index. Researchers also observed improvements in itch as early as week
    Read more ...